loading
Precedente Chiudi:
$0.94
Aprire:
$0.8801
Volume 24 ore:
7,109
Relative Volume:
0.04
Capitalizzazione di mercato:
$37.61M
Reddito:
-
Utile/perdita netta:
$-8.53M
Rapporto P/E:
-3.6196
EPS:
-0.2434
Flusso di cassa netto:
$-12.75M
1 W Prestazione:
-11.01%
1M Prestazione:
-11.01%
6M Prestazione:
-30.63%
1 anno Prestazione:
-5.27%
Intervallo 1D:
Value
$0.8701
$0.9196
Intervallo di 1 settimana:
Value
$0.87
$0.9899
Portata 52W:
Value
$0.63
$3.23

Estrella Immunopharma Inc Stock (ESLA) Company Profile

Name
Nome
Estrella Immunopharma Inc
Name
Telefono
(510) 318-9098
Name
Indirizzo
5858 HORTON STREET, SUITE 370, EMERYVILLE
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
ESLA's Discussions on Twitter

Confronta ESLA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ESLA
Estrella Immunopharma Inc
0.881 37.61M 0 -8.53M -12.75M -0.2434
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Estrella Immunopharma Inc Borsa (ESLA) Ultime notizie

pulisher
Jun 07, 2025

Estrella Immunopharma Expands STARLIGHT-1 Trial with New Texas Clinical Site - MSN

Jun 07, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma opens new trial site for cancer therapy By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II Starlight-1 Trial in B-Cell Non-Hodgkin's Lymphoma - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - BioSpace

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma (ESLA) Expands Clinical Trial with New Sit - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma opens new trial site for cancer therapy - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma Expands STARLIGHT-1 Clinical Trial - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma Announces Activation Of Additional Site For Phase I/Ii Starlight-1 Trial In B-Cell Non-Hodgkin'S Lymphoma - marketscreener.com

Jun 05, 2025
pulisher
Jun 04, 2025

Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | E - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Estrella Immunopharma secures $3.35 million in PIPE financing By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | ESLA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Estrella Immunopharma (ESLA) Secures $3.35M Through Private Equi - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Estrella Immunopharma secures $3.35 million in PIPE financing - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing - Business Wire

Jun 03, 2025
pulisher
May 30, 2025

Estrella Immunopharma’s (ESLA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World

May 30, 2025
pulisher
May 29, 2025

Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial - Yahoo

May 29, 2025
pulisher
May 29, 2025

ESLA Stock Rating and Price Target Maintained by D. Boral Capita - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma, Inc. Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma Advances STARLIGHT-1 Clinical Trial - TipRanks

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas - BioSpace

May 29, 2025
pulisher
May 29, 2025

ESLA Stock Rating and Price Target Maintained by D. Boral Capital | ESLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma (ESLA) Advances in Phase I/II STARLIGHT-1 Trial | ESLA Stock News - GuruFocus

May 29, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Acquires 16,862 Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) - Defense World

May 05, 2025
pulisher
Apr 24, 2025

ESLA Stock: A Voyage Through Estrella Immunopharma Inc’s Finances - investchronicle.com

Apr 24, 2025
pulisher
Apr 24, 2025

A stock that deserves closer examination: Estrella Immunopharma Inc (ESLA) - uspostnews.com

Apr 24, 2025
pulisher
Mar 05, 2025

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners - BioSpace

Mar 05, 2025
pulisher
Feb 22, 2025

Estrella Immunopharma completes first dose cohort in STARLIGHT trial - Yahoo Finance

Feb 22, 2025
pulisher
Feb 21, 2025

Sector Update: Health Care -February 21, 2025 at 03:42 pm EST - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose Cohort - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort - The Bakersfield Californian

Feb 21, 2025
pulisher
Feb 20, 2025

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital - 01net

Feb 20, 2025
pulisher
Feb 19, 2025

Estrella Immunopharma (NASDAQ:ESLA) Now Covered by Analysts at D. Boral Capital - Defense World

Feb 19, 2025
pulisher
Feb 18, 2025

This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Feb 18, 2025
pulisher
Dec 16, 2024

Estrella Immunopharma regains Nasdaq compliance - Investing.com

Dec 16, 2024
pulisher
Nov 25, 2024

Estrella Immunopharma faces Nasdaq delisting over equity shortfall - Investing.com

Nov 25, 2024
pulisher
Nov 14, 2024

Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider - Simply Wall St

Nov 14, 2024
pulisher
Nov 11, 2024

Eureka Therapeutics Tackling Advanced Hepatocellular Carcinoma With T-Cell Therapy ECT204 in Phase 1/2 ARYA-3 Clinical Trial - CGTLive™

Nov 11, 2024
pulisher
Nov 07, 2024

Estrella Immunopharma Appoints Dr. Cheng Liu as CEO - TipRanks

Nov 07, 2024
pulisher
Oct 31, 2024

Tesla stock hits 52-week low at $0.75 amid market challenges - Investing.com

Oct 31, 2024
pulisher
Oct 09, 2024

Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™

Oct 09, 2024
pulisher
Oct 03, 2024

First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas - CGTLive®

Oct 03, 2024
pulisher
Sep 27, 2024

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS - Business Wire

Sep 27, 2024

Estrella Immunopharma Inc Azioni (ESLA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Capitalizzazione:     |  Volume (24 ore):